Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: SCALORBI F
Authors: Scalorbi F, Mazzaglia S, Maccauro M, Chiesa C, Prinzi N,
Keywords: prrt, healthy tissue and target lesion dosimetry, gastroenteropancreatic neuroendocrine tumor,
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,
Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,
Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Strosberg J
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,